Using a multiplicity of molecular approaches, City of Hope researchers have identified a diverse range of novel colorectal cancer biomarkers, including DNA, MRNA, microRNA and DNA methylation-based biomarkers.
 
The potential clinical applications of these biomarkers are broad, and include diagnosis, prognosis, treatment prediction and monitoring of colorectal and other GI cancers, as well as patient stratification for clinical trials.